Skip to main content
ACG 2025 Annual Meeting Main banner
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Award Winner
ACG Newsworthy Abstract
ACG Newsworthy Abstract
Registration Required
Registration Required
No CME
No CME
On-Demand Video
On-Demand Video
Livestream
Livestream

Tuesday Poster Session

Category: Liver

P5817 - SGLT2 Inhibitors and Clinical Outcomes in Patients With Primary Biliary Cholangitis and Type 2 Diabetes: A Global Cohort Study

Tuesday, October 28, 2025
10:30 AM - 4:00 PM MT
Location: Exhibit Hall
Mohamad-Noor Abu-Hammour, MD1, Barish Eren, MD2, Mohammad Alabbas, MD3, Walid Hazem, DO4, Omar Sims, PhD5, Dian Jung Chiang, MD1
1Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic Foundation, Cleveland, OH; 3Cleveland Clinic Foundation, South Euclid, OH; 4University Hospitals Cleveland Medical Center, Cleveland, OH; 5Cleveland Clinic Foundation, Hoover, AL

Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used in diabetes management, demonstrating cardiovascular and renal benefits. Emerging evidence has revealed potential benefit in liver-related outcome in metabolic dysfunction associated steatotic liver disease (MASLD) and cirrhosis. However, its impact on liver related outcomes in primary biliary cholangitis (PBC) populations with DM remains to be determined. This study evaluated clinical outcomes associated with SGLT2i use in patients with PBC and T2DM in a large research database.

Methods: A retrospective cohort analysis using TriNetX data was conducted. Patients diagnosed with PBC and T2DM were stratified into those receiving SGLT2i (n=1,198) and those not receiving SGLT2i (n=1,198), matched using propensity scoring for demographics, comorbidities, medications, and labs. Outcomes assessed over 12 months included ascites, jaundice, hepatic encephalopathy (HE), hepatocellular carcinoma (HCC), mortality (ACM), and hospitalizations (ACH). Outcomes were reported as risk ratios (RR) with 95% confidence intervals.

Results: Patients on SGLT2i were associated with significantly reduced risks of developing ascites (RR=0.62, 95% CI: 0.51–0.76), jaundice (RR=0.61, 95% CI: 0.38–0.98), all-cause mortality (RR=0.60, 95% CI: 0.45–0.81), and hospitalizations (RR=0.79, 95% CI: 0.69–0.91). No significant associations were observed for hepatic encephalopathy (RR=0.80, 95% CI: 0.58–1.10), hepatocellular carcinoma (RR=0.84, 95% CI: 0.53–1.34), and variceal bleeding (RR=0.64, 95% CI: 0.33–1.24).

Discussion: In this matched cohort analysis, SGLT2 inhibitor use in patients with PBC and T2DM was associated with significantly lower risks of ascites, jaundice, mortality, and hospitalizations. Prospective studies are warranted to further analyze these findings and explore underlying mechanisms.

Disclosures:
Mohamad-Noor Abu-Hammour indicated no relevant financial relationships.
Barish Eren indicated no relevant financial relationships.
Mohammad Alabbas indicated no relevant financial relationships.
Walid Hazem indicated no relevant financial relationships.
Omar Sims indicated no relevant financial relationships.
Dian Jung Chiang: Ipsen – Advisory Committee/Board Member.

Mohamad-Noor Abu-Hammour, MD1, Barish Eren, MD2, Mohammad Alabbas, MD3, Walid Hazem, DO4, Omar Sims, PhD5, Dian Jung Chiang, MD1. P5817 - SGLT2 Inhibitors and Clinical Outcomes in Patients With Primary Biliary Cholangitis and Type 2 Diabetes: A Global Cohort Study, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.